Optimal treatment of early-stage ovarian cancer

Collinson, F, Qian, W, Fossati, R, Lissoni, A, Williams, C, Parmar, M, Ledermann, J, Colombo, N, Swart, A and , on behalf of the ICON1 collaborators (2014) Optimal treatment of early-stage ovarian cancer. Annals of Oncology, 25 (6). pp. 1165-1171. ISSN 0923-7534

Full text not available from this repository. (Request a copy)

Abstract

There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International Collaborative Ovarian Neoplasm (ICON)1 trial demonstrated benefit in both overall survival (OS) and recurrence-free survival (RFS) with adjuvant chemotherapy. We report results of 10-year follow-up to establish whether benefits are maintained longer-term and discuss how this and other available evidence from randomised trials can be used to guide treatment options regarding the need for, and choice of, adjuvant chemotherapy regimen.

Item Type: Article
Uncontrolled Keywords: early-stage ovarian cancer,adjuvant chemotherapy,icon1,icon3
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 30 May 2014 20:08
Last Modified: 21 Apr 2020 23:01
URI: https://ueaeprints.uea.ac.uk/id/eprint/48507
DOI: 10.1093/annonc/mdu116

Actions (login required)

View Item View Item